EX-10.26



 Exhibit 10.26 

CONSENT AND AMENDMENT AGREEMENT 

This Consent and Amendment Agreement (this “Agreement”), dated as of November 19, 2012, is entered into by and
among SYNDAX PHARMACEUTICALS, INC., a Delaware corporation (“Borrower”), the Lenders (as defined below), and GENERAL ELECTRIC CAPITAL CORPORATION, as agent for the Lenders (in such capacity, and together with its successors
and permitted assigns, “Agent”). 
 WHEREAS, pursuant to that certain Loan and Security Agreement, dated as
of March 30, 2011, as amended by that certain Consent and Amendment Agreement, dated as of December 20, 2011, as further amended by that certain Consent and Amendment Agreement, dated as of June 28, 2012, and as further amended by
that certain Consent and Amendment Agreement, dated as of October 9, 2012, each among Borrower, Agent and the financial institutions party thereto as lenders (the “Lenders”; the Loan and Security Agreement, as so amended
and as it may have been and may be further amended, restated or otherwise modified from time to time, the “Loan Agreement”), Agent and the Lenders have made certain loans and other financial accommodations to Borrower subject
to the terms and conditions set forth therein; 
 WHEREAS, Borrower has requested that Agent and Requisite Lenders consent to the
incurrence by Borrower of up to $1,000,000 of additional unsecured, subordinated Indebtedness evidenced by a new series of Unsecured Convertible Promissory Notes, dated on or about the date hereof (the “Series B Convertible
Notes”), issued under that certain Note Purchase Agreement, dated on or about the date hereof (the “NPA”), by and among Borrower and the investors party thereto, which Indebtedness (i) shall be subordinated
to all Obligations in all respects pursuant to a Subordination Agreement, dated as of the date hereof (the “Subordination Agreement”), executed by Borrower and each investor that is purchasing a Series B Convertible Note;
(ii) shall not require payment of any kind (including principal, interest, fees or other costs related thereto) until all Obligations shall have been indefeasibly paid in full; provided, that such financing may be converted to equity at
any time and payment of cash in lieu of the issuance of fractional shares in connection with such conversion may be made; and (iii) shall otherwise be in form and substance reasonably satisfactory to Agent; 

WHEREAS, in connection with the issuance of the Series B Convertible Notes, Borrower has further requested that Agent and Requisite
Lenders consent to the amendment by Borrower of its certificate of incorporation in the form of the Certificate of Amendment to Fifth Amended and Restated Certificate of Incorporation attached hereto as Exhibit A (the “November
2012 Charter Amendment”) to, among other things, authorize the Series B Preferred Stock (the “Series B Preferred Stock”) into which the Series B Convertible Notes may be convertible in accordance with the terms
thereof; 
 WHEREAS, pursuant to that certain Note Purchase Agreement, dated as of October 9, 2012 (the “October 2012
NPA”), by and among the Borrower and the investors party thereto, Borrower issued to the purchasers under the October 2012 NPA unsecured convertible promissory notes in the aggregate principal amount of $750,000 (the “October
2012 Notes”); 
 WHEREAS, Borrower has requested that Agent and Requisite Lenders consent to the amendment of the
October 2012 Notes in the form of the Amendment to Convertible Promissory Notes attached hereto as Exhibit B (the “October 2012 Notes Amendment”) to, among other things, convert the October 2012 Notes automatically
into shares of Series B Preferred Stock upon the issuance and sale of Series B Preferred Stock in an equity financing with total proceeds to Borrower of not less than $30,000,000; 







 WHEREAS, Borrower has requested that Agent and Requisite Lenders consent to the foregoing,
which, but for this Agreement, would be prohibited under Sections 7.2 and 7.11 of the Loan Agreement; 
 WHEREAS, pursuant to
Section 6.2(a) of the Loan Agreement, Borrower is required to notify Agent of any change in the accuracy of the Perfection Certificate, immediately upon the occurrence of any such change, and Borrower has failed to notify Agent of certain
changes thereto, as more fully detailed on Schedule 1 hereto, which such failure constitutes an Event of Default under Section 8.1(b) of the Loan Agreement (the “Perfection Certificate Notification Event of
Default”); 
 WHEREAS, pursuant to Section 6.2(e) of the Loan Agreement, Borrower is required to notify Agent with
respect to any new applications or registrations that any Loan Party has made or filed in respect of any Intellectual Property or a change in status of any outstanding application or registration within five (5) days of such application,
registration, filing or change in status, and Borrower has failed notify agent with respect to the items more fully described on Schedule 2 hereto, which such failure constitutes an Event of Default under Section 8.1(b) of the Loan
Agreement (the Intellectual Property Notification Event of Default, and, together with the Perfection Certificate Notification Event of Default, the “Identified Events of Default”); 

WHEREAS, Borrower has requested that Agent and Requisite Lenders waive, ab initio, each Identified Event of Default; and 

WHEREAS, Agent and Lenders constituting at least the Requisite Lenders are willing to agree to such requests, subject to and in
accordance with the terms and conditions set forth in this Agreement. 
 NOW, THEREFORE, each of Borrower, Requisite Lenders and
Agent hereby agrees as follows: 
 1. Recitals; Definitions. The foregoing recitals, including all terms defined therein, are
incorporated herein and made a part hereof. All capitalized terms used but not otherwise defined herein have the meanings given such terms in the Loan Agreement. 

2. Consent and Waiver. Effective as of the date hereof, and in accordance with Section 10.08 of the Loan Agreement, Agent
and Lenders constituting at least the Requisite Lenders hereby (i) consent to (A) the issuance of the Series B Convertible Notes, the execution and delivery of the NPA and the other documents related thereto, and the incurrence of the
Indebtedness under the NPA, (B) the execution and delivery of the November 2012 Charter Amendment and (C) the execution and delivery of the October 2012 Notes Amendment and (ii) waive, ab initio, each Identified Event of
Default. 
 3. Amendments. Subject to the terms and conditions of this Agreement, Section 7.2 of the Loan Agreement is
hereby amended by deleting clause (d) thereof in its entirety and replacing such clause with the following: 
 (d) subordinated,
unsecured Indebtedness in an aggregate amount not to exceed $17,000,000 (the “Subordinated Indebtedness”), which subordinated, unsecured Indebtedness is evidenced by those certain Convertible Promissory Notes issued pursuant to
(i) that certain Note and Warrant Purchase Agreement, dated as of August 3, 2010, by and among Borrower and each investor party thereto (the “2010 NPA”); (ii) that certain Note and Warrant Purchase Agreement, dated as
of December 20, 2011 (the “2011 NPA”), as amended by that certain Amendment to Note and Warrant Purchase Agreement, dated as of June 28, 2012, each by and among Borrower and each investor party thereto (the 2011


  
 2 








 
NPA, as so amended, the “June 2012 NPA”); (iii) that certain Note Purchase Agreement, dated as of October 9, 2012, by and among Borrower and each investor party thereto
(the “October 2012 NPA”); and (iv) that certain Note Purchase Agreement, dated as of November 19, 2012, by and among Borrower and each investor party thereto (the “November 2012 NPA”), which Indebtedness
is subordinated to the Obligations pursuant to (A) that certain Subordination Agreement, dated as of March 30, 2011, by and among Agent and certain investors party to that certain Note and Warrant Purchase Agreement, dated as of
August 3, 2010 (which subordinates $6,000,000, the “First Subordination Agreement”); (B) that certain Amended and Restated Subordination Agreement, dated as of December 20, 2011, by and among each of the parties to
the First Subordination Agreement and certain other investors who are parties to the 2011 NPA (which amends, restates and continues the First Subordination Agreement subordinating an additional $6,250,000 for a total of $12,250,000, the
“2011 Subordination Agreement”); (C) that certain Subordination Agreement, dated as of June 28, 2012, by and among the parties to the First Subordination Agreement and the 2011 Subordination Agreement other than two
individual investors who have opted not to participate in the offering under the 2012 NPA (which Subordination Agreement separately subordinates $3,000,000 (the “June 2012 Subordination Agreement”); (D) that certain
Subordination Agreement, dated as of October 9, 2012, by and among the holders of the Borrower’s Series A Preferred Stock on the date thereof (which Subordination Agreement separately subordinates $750,000, the “October 2012
Subordination Agreement”); and (E) that certain Subordination Agreement, dated as of November 19, 2012, by and among the holders of the Borrower’s Series A Preferred Stock on the date thereof (which Subordination Agreement
separately subordinates $1,000,000, the “November 2012 Subordination Agreement”, and together with the 2011 Subordination Agreement (which, for the avoidance of doubt, includes the First Subordination Agreement), the June 2012
Subordination Agreement, and the October 2012 Subordination Agreement, collectively, the “Subordination Agreements”). 
 4.
Conditions. The foregoing is subject to the following conditions: 
  

	 	A.	Agent shall have received a counterpart of this Agreement duly executed by each Loan Party; 

  

	 	B.	Agent shall have received a counterpart of the Subordination Agreement duly executed by each investor that is purchasing Series B Convertible Note pursuant to the NPA and consented to by Borrower; 


 

	 	C.	Borrower shall have delivered a certificate of an authorized officer of Borrower, providing verification of an incumbency and attaching (i) Borrower’s board resolutions approving the transactions contemplated
by this Agreement and (ii) Borrower’s governing documents; 

  

	 	D.	Borrower shall have delivered true and complete copies of the Series B Convertible Notes, the NPA, the November 2012 Charter Amendment, the October 2012 Notes Amendment and the other amendments referenced herein and
such further documents, information, certificates, records and filings as Agent may reasonably request; and 


  
 3 









	 	E.	(i) No Default or Event of Default shall have occurred and be continuing other than the Defaults or Events of Default waived pursuant to Section 2 above, (ii) all representations and warranties in
Section 5 of the Loan Agreement shall be true and correct as of the date hereof, (iii) each condition set forth in this Section 4 of this Agreement shall have been satisfied, and (iv) Agent shall have received a certificate from
an authorized officer of Borrower confirming each of the foregoing. 

 5. Reaffirmation of Debt Documents. By
executing and delivering this Agreement, Borrower hereby (i) reaffirms, ratifies and confirms its Obligations under the Loan Agreement, the Notes and the other Debt Documents; (ii) agrees that this Agreement shall be a “Debt
Document” under the Loan Agreement; and (iii) hereby expressly agrees that the Loan Agreement, the Notes and each other Debt Document shall remain in full force and effect following any action contemplated in connection herewith. 

6. Reaffirmation of Grant of Security Interest in Collateral. Borrower hereby expressly reaffirms, ratifies and confirms its
obligations under the Loan Agreement, including its mortgage, grant, pledge and hypothecation to Agent for the benefit of Agent and each Lender, of the lien on and security interest in, all of its right, title and interest in, all of the Collateral.

 7. Confirmation of Representations and Warranties; Liens; No Default. Borrower hereby confirms that (i) all of the
representations and warranties set forth in the Debt Documents continue to be true and correct as of the date hereof, except to the extent such representations and warranties by their terms expressly relate only to a prior date (in which case such
representations and warranties shall be true and correct as of such prior date); (ii) there are no Defaults or Events of Default that have not been waived or cured other than the Defaults or Events of Default waived pursuant to
Section 2 above; (iii) Agent has and shall continue to have valid, enforceable and perfected first-priority liens, subject to Permitted Liens, on and security interests in the Collateral and all other collateral heretofore granted
by Borrower to Agent, for the benefit of Agent and each Lender, pursuant to the Debt Documents or otherwise granted to or held by Agent, for the benefit of Agent and each Lender; and (iv) the agreements and obligations of Borrower contained in
the Debt Documents and in this Agreement constitute the legal, valid and binding obligations of Borrower, enforceable against Borrower in accordance with their respective terms, except as the enforceability thereof may be limited by bankruptcy,
insolvency or other similar laws of general application affecting the enforcement of creditors’ rights or by the application of general principles of equity; provided, however, with respect to this clause (iv), to the extent that this Agreement
is not enforceable against Borrower, the obligations of Agent and the Lenders contained herein with respect to such parties are null and void. 

8. No Other Consents or Amendments. The consent and waiver in this Agreement are applicable only to the matters set forth in
Section 2 above, and do not constitute a future consent or waiver nor a consent to, or waiver of, anything other than the matters expressly set forth herein including, for the avoidance of doubt, any other transactions involving the sale
or issuance of the Series B Preferred Stock. Except as expressly set forth in this Agreement, the Loan Agreement and all other Debt Documents shall remain unchanged and in full force and effect. This Agreement shall be limited precisely and
expressly as drafted and shall not be construed as consent to the amendment, restatement, modification, supplementation or waiver of any other terms or provisions of the Loan Agreement or any other Debt Document. 

9. Costs and Expenses. Borrower shall be responsible for (i) a consent fee of $1,500.00 and (ii) the reimbursement of
all fees and expenses of Agent’s in-house and outside counsel and other out of pocket costs and expenses incurred by Agent and the Lenders in connection with the preparation and 

  
 4 








 
negotiation of this Agreement. Such fees, costs and expenses, as limited by the preceding sentence, shall be due and payable upon demand of Agent, and if not paid promptly upon such demand, all
such fees, costs and expenses shall become part of the Obligations. 
 10. Governing Law. This Agreement shall be governed by
and construed in accordance with the laws of the State of New York. 
 11. Successors/Assigns. This Agreement shall bind, and
the rights hereunder shall inure to, the respective successors and assigns of the parties hereto, subject to the provisions of the Debt Documents. 

12. Headings. Section headings in this Agreement are included for convenience of reference only and shall not constitute a part
of this Agreement for any other purpose. 
 13. Counterparts. This Agreement may be executed in counterparts, and such
counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of an executed counterpart of this Agreement by facsimile or other electronic method of transmission shall be equally as effective as delivery of an
original executed counterpart of this Agreement. Any party delivering an executed counterpart of this Agreement by facsimile or other electronic method of transmission also shall deliver an original executed counterpart of this Agreement but the
failure to deliver an original executed counterpart shall not affect the validity, enforceability or binding effect of this Agreement. 

[SIGNATURE PAGE TO FOLLOW] 

  
 5 








 IN WITNESS WHEREOF, the undersigned have caused this Consent and Amendment Agreement to be
duly executed by their duly authorized representatives, all as of the day and year first above written. 
  

			
	 BORROWER:
  

Syndax Pharmaceuticals, Inc., a Delaware corporation

		
	By:	 	/s/ Arlene M. Morris
	Name:	 	Arlene M. Morris
	Title:	 	Chief Executive Officer


 [Signatures Continue on Following Page] 

  
 S-1 








 
			
	 AGENT AND LENDER:
  

General Electric Capital Corporation, a Delaware corporation

		
	By:	 	/s/ Jacqueline K. Blechinger
	Name:	 	Jacqueline K. Blechinger
	Its:	 	Duly Authorized Signatory


 [End of Signature Pages] 

  
 S-2 








 Exhibit A 

November 2012 Charter Amendment 

  
 Exhibit A 








 CERTIFICATE OF AMENDMENT 

TO 
 FIFTH AMENDED AND
RESTATED 
 CERTIFICATE OF INCORPORATION 

OF 
 SYNDAX
PHARMACEUTICALS, INC. 
 SYNDAX PHARMACEUTICALS, INC., a corporation organized and existing under and by virtue of the General
Corporation Law of the State of Delaware (the “Corporation”), DOES HEREBY CERTIFY: 
 FIRST: That resolutions setting
forth a proposed amendment to the Fifth Amended and Restated Certificate of Incorporation of the Corporation, declaring said amendment to be advisable and directing that said amendment be considered by the stockholders of the Corporation, were duly
adopted by the Board of Directors of the Corporation, acting by unanimous written consent. 
 SECOND: That said amendment was approved by
the stockholders of the Corporation entitled to vote on such amendment acting by written consent in accordance with the provisions of Section 228 of the General Corporation Law of the State of Delaware. 

THIRD: That said amendment amends the Fifth Amended and Restated Certificate of Incorporation of the Corporation by deleting the existing
Article IV of said Certificate of Incorporation in its entirety and substituting therefor a new Article IV to read in its entirety as follows: 

ARTICLE IV 
 This
corporation is authorized to issue two classes of stock to be designated, respectively, “Common Stock” and “Preferred Stock.” The total number of shares which this corporation is authorized to issue is Two Hundred
Seventy-Five Million Three Hundred Thousand (275,300,000) shares. One Hundred Sixteen Million Six Hundred Fifty Thousand (116,650,000) shares shall be Common Stock with a par value of $0.0001 per share and One Hundred Fifty-Eight Million
Six Hundred Fifty Thousand (158,650,000) shares shall be Preferred Stock with a par value of $0.001 per share, Seventy-Eight Million (78,000,000) of which shall be designated Series A Preferred Stock (“Series A Preferred
Stock”), Seventy-Eight Million (78,000,000) of which shall be designated Series A-1 Preferred Stock (“Series A-1 Preferred Stock” and together with the Series A Preferred Stock, the “Series A/A-1 Preferred
Stock”) and Two Million Six Hundred Fifty Thousand (2,650,000) of which shall be designated Series B Preferred Stock (“Series B Preferred Stock” and together with the Series A/A-1 Preferred Stock, the
“Preferred Stock”). This corporation shall from time to time in accordance with the laws of the State of Delaware increase the authorized amount of its Common Stock if at any time the number of shares of Common Stock remaining
unissued and available for issuance upon conversion of the Preferred Stock shall not be sufficient to permit conversion of the Preferred Stock. Subject to the provisions herein, the number of authorized shares of Common Stock may be increased or
decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of shares of stock of this corporation representing a majority of the votes represented 


  








 
by all outstanding shares of stock of this corporation entitled to vote, irrespective of the provisions of Section 242(b)(2) of the Delaware General Corporation Law. 

FOURTH: That said amendment was duly adopted in accordance with the applicable provisions of Sections 242 and 228 of the General Corporation
Law of the State of Delaware. 
 IN WITNESS WHEREOF, the Corporation has caused this Certificate of Amendment to be executed by Arlene M.
Morris, its Chief Executive Officer, this 19th day of November, 2012. 
  

			
	SYNDAX PHARMACEUTICALS, INC.
		
	By:	 	/s/ Arlene M. Morris
	Name:	 	Arlene M. Morris
	Title:	 	Chief Executive Officer









 Exhibit B 

October 2012 Notes Amendment 

  
 Exhibit B 








 AMENDMENT TO CONVERTIBLE PROMISSORY NOTES 

This AMENDMENT TO CONVERTIBLE PROMISSORY NOTES (this “Amendment”) is made and entered into as of the
[    ] day of November, 2012, by and among Syndax Pharmaceutics, Inc., a Delaware corporation (the “Company”), and the Purchasers (as hereinafter defined) executing this Amendment. 

RECITALS 
 WHEREAS,
the Company intends to engage in an equity financing in which it intends to issue shares of its Series B Preferred Stock (the “Series B Financing”); 

WHEREAS, the Company and the Purchasers entered into that certain Note Purchase Agreement dated as of October 9, 2012 (the
“October Purchase Agreement”) by and among the Company and the parties named on the Schedule of Purchasers attached thereto (the “Purchasers”) in connection with a bridge financing (the
“October Bridge Financing”) for the purpose of providing capital to fund operations in anticipation of the consummation of the Series B Financing; 

WHEREAS, pursuant to the October Purchase Agreement, the Company issued to the Purchasers convertible promissory notes (the
“October Notes”); 
 WHEREAS, the Company is engaging in an additional bridge financing on the date hereof in
which the Company will issue convertible promissory notes to the Purchasers (the “November Notes”) for the purpose of providing additional capital to fund operations until the consummation of the Series B Financing; 

WHEREAS, the understanding and intention of the Company and the Purchasers is that both the October Notes and the November Notes will
automatically convert into shares of Series B Preferred Stock upon an equity financing of not less than $30,000,000; and 
 WHEREAS,
the October Notes may be amended with the written consent of the Company and the holders of a majority-in-interest of the then outstanding principal amount of the October Notes and the signatories hereto constitute a majority-in-interest thereof.

 NOW, THEREFORE, in consideration of the mutual covenants herein contained and other valuable consideration, the parties, intending
to be legally bound, hereby agree as follows: 
 1. Amendment. Section 2.(a) of each October Note is hereby amended by
deleting the existing Section 2.(a) in its entirety and substituting therefor a new Section 2.(a) to read in its entirety as follows: 

(a) In the event that the Company issues and sells shares of a newly authorized series of Preferred Stock (the “Series B Preferred
Stock”) to investors (the “Investors”) in an equity financing with total proceeds to the Company of not less than $30,000,000 (including the conversion or potential conversion of the Notes and the promissory
notes issued by the Company on November [    ], 2012, but not other debt) (a “Qualified Financing”) and the Notes have not been paid in full, then the outstanding principal balance and all unpaid accrued
interest, net of any required withholding taxes, of this Note shall automatically convert in whole into shares of Series B Preferred Stock at a conversion price equal to eighty percent (80%) of the price per share paid by the Investors








 
purchasing the Series B Preferred Stock on the same terms and conditions as given to the Investors in the Qualified Financing, provided, however, that the Holder shall be given prior notice of
any such Qualified Financing 
 2. Miscellaneous. 

(a) Except as expressly set forth in this Amendment, there have been no other changes or modifications to the October Notes, and the October
Notes remain unchanged and in full force and effect. 
 (b) This Amendment may be executed in any number of counterparts, each of which when
so executed and delivered shall be an original, but all of which shall constitute one and the same instrument. 
 [SIGNATURE PAGES
FOLLOW] 







 IN WITNESS WHEREOF, the parties have executed this Amendment as of the day and year first written
above. 
  

			
	 COMPANY:
  

SYNDAX PHARMACEUTICALS, INC.

		
	 By:
	 	 
	 Name:
	 	Arlene M. Morris
	 Title:
	 	Chief Executive Officer


 Company Signature Page to October 2012 Convertible Note Amendment 

  








 
			
	 PURCHASERS:
  

	A.M. PAPPAS LIFE SCIENCE VENTURES III, L.P.
	 By:

Its:
	 	 AMP&A Management III, LLC
 General
Partner

		
	By:	 	 
	Name:	 	Ford S. Worthy
	Title:	 	Partner and Chief Financial Officer


  

			
	PV III CEO FUND, L.P.
	 By:
	 	AMP&A Management III, LLC
	 Its:
	 	General Partner
		
	By:	 	 
	Name:	 	Ford S. Worthy
	Title:	 	Partner and Chief Financial Officer



  
 Purchaser Signature Pages
to October 2012 Convertible Note Amendment 








 
			
	 PURCHASERS:
  

AVALON VENTURES VII, L.P.

	 BY:
 Its:
	 	 AVALON VENTURES VII GP, LLC
 General
Partner

		
	By:	 	 
	Name:	 	Kevin Kinsella
	Title:	 	Managing Member



  
 Purchaser Signature Pages
to October 2012 Convertible Note Amendment 








 
			
	 PURCHASERS:
  

DOMAIN PARTNERS VI, L.P.

	 By:
 Its:
	 	 One Palmer Square Associates VI, L.L.C.
 General
Partner

		
	By:	 	 
	Name:	 	Kathleen K. Schoemaker
	Title:	 	Managing Member



  
 Purchaser Signature Pages
to October 2012 Convertible Note Amendment 








 
			
	 PURCHASERS:
  

FORWARD VENTURES V, LP

	By:	 	Forward V Associates, LLC
	Its:	 	General Partner
		
	By:	 	 
	Name:	 	Ivor Royston, M.D.
	Title:	 	Managing Member


  

			
	FORWARD VENTURES IV, LP
	 By:
 Its:
	 	 Forward IV Associates, LLC
 General
Partner

		
	By:	 	 
	Name:	 	Ivor Royston, M.D.
	Title:	 	Managing Member


  

			
	FORWARD VENTURES IVB, LP
	 By:
 Its:
	 	 Forward IV Associates, LLC
 General
Partner

		
	By:	 	 
	Name:	 	Ivor Royston, M.D.
	Title:	 	Managing Member



  
 Purchaser Signature Pages
to October 2012 Convertible Note Amendment 








 
			
	 PURCHASERS:
  

MPM BIOVENTURES IV-QP, L.P.

	By: MPM BioVentures IV GP LLC, Its General Partner
	By: MPM BioVentures IV LLC, Its Managing Member
		
	 By:
	 	 
	Name:	 	Luke Evnin, Ph.D. 
	Title:	 	Member


  

			
	 MPM BIOVENTURES IV GMBH & CO.

BETEILIGUNGS KG

	By: MPM BioVentures IV GP LLC, in its capacity as the Managing Limited Partner
	By: MPM BioVentures IV LLC, Its Managing Member
		
	 By:
	 	 
	Name:	 	Luke Evnin, Ph.D. 
	Title:	 	Member


  

			
	MPM ASSET MANAGEMENT INVESTORS BV4 LLC By: MPM BioVentures IV LLC, its Manager
		
	 By:
	 	 
	Name:	 	Luke Evnin, Ph.D. 
	Title:	 	Member


  

			
	MPM BIOVENTURES IV STRATEGIC FUND, L.P.
	 By: MPM BioVentures IV GP LLC, Its General Partner

	By: MPM BioVentures IV GP LLC, Its Managing Member
		
	 By:
	 	 
	Name:	 	Luke Evnin, Ph.D. 
	Title:	 	Member



  
 Purchaser Signature Pages
to October 2012 Convertible Note Amendment 








 
			
	 PURCHASERS:
  

MC LIFE SCIENCE VENTURES, INC.

		
	By:	 	 
	Name:	 	Yasuaki Matsuo
	Title:	 	Executive Vice President



  
 Purchaser Signature Pages
to October 2012 Convertible Note Amendment 








 Schedule 1 

Perfection Certificate Changes 

None. 

  
 Schedule 1 








 Schedule 2 

See Section 4 of the Perfection Certificate 

  
 Schedule 2